Incident urothelial cancer in the Malmö Diet and Cancer Study: Cohort characteristics and further validation of ezrin as a prognostic biomarker

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Wennersten, Christoffer ^a   Andersson, Gustav ^a   Boman, Karolina ^a   Nodin, Björn ^a   Gaber, Alexander ^a   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Ezrin; Malm Diet and Cancer; Prognosis; Urothelial cancer

Indexed keywords

CYTOSKELETON PROTEIN; EZRIN; TUMOR MARKER;

ADVERSE EFFECTS; AGED; BLADDER TUMOR; COHORT ANALYSIS; DIET; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TUMOR RECURRENCE; UROTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; CYTOSKELETAL PROTEINS; DIET; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84907960550     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-014-0189-5     Document Type: Article

References (31)

1. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013, 189(4):1214-1221. 10.1016/j.juro.2012.05.079, 23023150.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
3. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014, 83(4):863-867. 10.1016/j.urology.2013.10.060, 24485993.
4. Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl 2008, 218:45-54. 10.1080/03008880802283664, 18815916.
5. Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J 2006, 99(11):1256-1263. 10.1097/01.smj.0000247266.10393.72, 17195421.
6. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002, 98(2):274-278. 10.1002/ijc.10191, 11857419.
7. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000, 151(7):693-702. 10.1093/oxfordjournals.aje.a010264, 10752797.
8. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. Sci World J 2006, 6:2617-2625. 10.1100/tsw.2006.404.
9. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990, 322(16):1129-1138. 10.1056/NEJM199004193221607, 2181313.
10. Masood S, Sriprasad S, Palmer JH, Mufti GR. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 2004, 36(1):41-44. 10.1023/B:UROL.0000032688.37789.7c, 15338671.
11. Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995, 6(2):113-126. 7786818.
12. Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. Eur Urol 2009, 56(5):829-836. 10.1016/j.eururo.2008.09.062, 18926620.
13. Athanasopoulou A, Aroukatos P, Nakas D, Repanti M, Papadaki H, Bravou V. Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression. Urol Oncol 2013, 31(6):836-842. 10.1016/j.urolonc.2011.07.003, 21868260.
14. Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlen M, Segersten U, Malmstrom PU, Jirstrom K. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol 2014, 14:36. 10.1186/1471-2490-14-36, 24885195.
15. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study: design and feasibility. J Intern Med 1993, 233(1):45-51. 10.1111/j.1365-2796.1993.tb00647.x, 8429286.
16. Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlen M, Jirstrom K, Malmstrom PU. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol 2013, 13(1):17. 10.1186/1471-2490-13-17, 23565664.
17. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010, 102(6):365-367. 10.1093/jnci/djq031, 20208016.
18. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011, 60(3):397-411. 10.1136/gut.2010.217182, 21036793.
19. Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014, 109(8):1205-1214. 10.1038/ajg.2014.153, 24935274.
20. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6(5):963-968. 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q, 13094644.
21. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol 1999, 30(10):1197-1200. 10.1016/S0046-8177(99)90037-0, 10534167.
22. Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 2014, doi:10.1038/modpathol.2014.81. [Epub ahead of print].
23. Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C. Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol 2013, 8:17. 10.1186/1746-1596-8-17, 23379971.
24. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012, 7:42. 10.1186/1746-1596-7-42, 22515559.
25. Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Gaber A, Lindgren A, Jirstrom K, Bjartell A. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011, 24(5):708-719. 10.1038/modpathol.2010.238, 21240253.
26. Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 2005, 95(6):791-793. 10.1111/j.1464-410X.2005.05402.x, 15794784.
27. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52(4):594-601. 10.1016/S0090-4295(98)00295-7, 9763077.
28. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC. Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007, 177(5):1715-1720. 10.1016/j.juro.2007.01.030, 17437794.
29. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 2013, 31(7):1171-1177. 10.1016/j.urolonc.2012.01.011, 22534087.
30. Larsson AH, Nodin B, Syk I, Palmquist I, Uhlen M, Eberhard J, Jirstrom K. Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases. Diagn Pathol 2013, 8:109. 10.1186/1746-1596-8-109, 23819542.
31. Larsson A, Fridberg M, Gaber A, Nodin B, Leveen P, Jonsson G, Uhlen M, Birgisson H, Jirstrom K. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer 2012, 12:282. 10.1186/1471-2407-12-282, 22769594.